Results 131 to 140 of about 5,561 (172)

Serum Metabolomic Signatures Indicate Oxidative Membrane Lipid Remodeling in β-Thalassemia. [PDF]

Metabolites
Makis A, Hatzimichael E, Palianopoulos T, Papagiannaki D, Kapsali E, Gikas E, Sakkas V.   +6 more
europepmc   +1 more source

Tb doped carbon dots as a platform for fluorescence ratiometric and colorimetric sensor for deferasirox. [PDF]

Sci Rep
Latifi F, Amjadi M, Hallaj T, Alavi SMS.
europepmc   +1 more source

Luspatercept for the treatment of transfusion-dependent non-severe aplastic anemia. [PDF]

Ann Hematol
Jia X, Zheng R, Hong Y, Ge H, Shen Y, Zhou Y, Yang X, Wu D.   +7 more
europepmc   +1 more source

A clinical-stage oncology compound selectively targets drug-resistant cancers

Long K, Bhattacharjee D, Newman-Stonebraker SH, Suhr S, Mercado BQ, Scheib E, Tighe A, Romero L, Thompson SL, Sausville EL, John KM, Julian L, Mishra S, Klingbeil O, Gupta P, Bhatt U, Gao AC, Ricardo S, Vakoc CR, Bornhauser BC, Corsello SM, Taylor SS, Chen J, Holland PL, Sheltzer JM.   +24 more
europepmc   +1 more source

Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia

Cancer Medicine, 2019
Deferasirox is an oral iron‐chelating agent having possible antileukemia and immune modulatory effects. Few reports have evaluated deferasirox in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the impact of
Byung‐Sik Cho, Young-Woo Jeon, Sung-Soo Park   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Deferasirox

Drugs, 2012
Lily P H Yang, Susan J Keam, Yang Lily P H   +2 more
exaly   +4 more sources

Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen

Journal of Clinical Pharmacology, 2008
Deferasirox (ICL670) is representative of a new class of tridentate iron chelators, formulated as tablets for dispersion. Deferasirox has exhibited high potency and a clinically manageable safety profile in preclinical models and in an extensive clinical
Antonio Piga, Maria Domenica Cappellini, Gian Luca Forni   +2 more
exaly   +3 more sources

Long-term efficacy and safety of deferasirox

Blood Reviews, 2008
Deferasirox is an oral iron chelator, with a long half-life, that can be given once daily, because it provides a 24-hour chelation. Several phase II trials and a pivotal phase III trial have established that, in transfusion-dependent patients with β ...
Maria Domenica Cappellini
exaly   +2 more sources

Deferasirox: An Update

Hemoglobin, 2009
Cumulative data from prospective studies in over 3,000 patients with a range of transfusion dependent anemias have established key principles about the efficacy and safety of deferasirox (DFS). Pivotal preregistration studies established the relationship between dose, iron excretion, and tolerability using changes in liver iron concentration (LIC) to ...

exaly   +3 more sources